clinical trial · NCT07075640
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
Healthy ParticipantsAG-236Placebo
brief summary
The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.
started
Jul 7, 2025
primary completion
Mar 25, 2026
completion
Aug 31, 2026
last updated
Mar 20, 2026
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol